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Abstract 29 
Context: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a poor 30 
prognosis.  Although the majority of childhood ACC arises in the context of inherited cancer 31 
susceptibility syndromes, it remains less clear whether a hereditary tumour predisposition exists 32 
for the development of ACC in adults. Here, we report the first occurrence of familial ACC in 33 
a kindred with Lynch syndrome due to a pathogenic germline MSH2 mutation.  34 
 35 
Case: A 54-year-old female, with a history of ovarian and colorectal malignancy, was found to 36 
have an ACC. A detailed family history revealed her mother had died of ACC and her sister 37 
had previously been diagnosed with endometrial and colorectal cancers. A unifying diagnosis 38 
of Lynch syndrome was considered, and immunohistochemical analyses demonstrated loss of 39 
MSH2 and MSH6 expression in both adrenocortical carcinomas (proband and her mother), and 40 
in the endometrial carcinoma of her sister. Subsequent genetic screening confirmed the 41 
presence of a germline MSH2 mutation (resulting in deletions of exons 1-3) in the proband and 42 
her sister. 43 
 44 
Conclusion: Our findings provide strong support for the recent proposal that ACC should be 45 
considered a Lynch syndrome associated tumour and included in the Amsterdam II clinical 46 
diagnostic criteria. We also suggest that screening for ACC should be considered in cancer 47 
surveillance strategies directed at individuals with germline mutations in DNA mismatch repair 48 
genes. 49 
 50 
  51 
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Introduction  52 
Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine cancer with an incidence 53 
of less than 1 case per million individuals per year (1). The majority of childhood ACC occurs 54 
in patients with familial cancer susceptibility syndromes such as Li-Fraumeni syndrome (LFS), 55 
but whether a hereditary tumour predisposition exists for the development of ACC in adults is 56 
less clear (1).  Whilst the majority of ACC in adulthood are sporadic, increasing evidence 57 
supports association between adult ACC and inherited cancer susceptibility syndromes 58 
including LFS, Multiple Endocrine Neoplasia type 1 and Lynch syndrome (LS)(1). However, 59 
given the low prevalence of ACC, ascertaining whether this cancer is a bona fide syndrome-60 
associated malignancy is challenging.  61 
 62 
Lynch syndrome is an autosomal dominant familial cancer syndrome caused by pathogenic 63 
germline mutations in one of several DNA mismatch repair (MMR) genes (MLH1, MSH2, 64 
MSH6 or PMS2), and associated with an estimated lifetime colorectal cancer risk of 80% (2).  65 
LS is also associated with an increased risk of several extra-colonic tumours (endometrial, 66 
stomach, small intestinal, hepatobiliary, urinary tract), which are therefore included as part of 67 
the Amsterdam II clinical diagnostic criteria for LS (2). In addition to these recognised cancers, 68 
previous reports have described a number of rare, non-classical cancers, including 69 
adrenocortical carcinoma (ACC), in patients with LS. Given the low prevalence of ACC it 70 
remains uncertain whether it is a true LS-associated tumour or arises independent of the primary 71 
genetic defect, although a recent study involving 114 subjects with primary ACC and 135 72 
probands from MMR gene-positive kindreds has provided important evidence for the former 73 
(3). 74 
 75 
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Here, we provide additional evidence to implicate ACC as a LS-associated cancer with the first 76 
description of an intergenerational (mother-to-daughter) occurrence of ACC in a family with 77 
LS due to a germline MSH2 mutation.  We therefore propose that ACC be included in clinical 78 
diagnostic criteria for LS and considered in cancer surveillance recommendations for 79 
individuals with germline mutations in DNA MMR genes.                                                                                  80 
81 
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Case History 82 
In 2001, the proband (Patient III:2), a 54-year old female, presented to her local hospital with 83 
right loin pain, lethargy and weight loss. She had previously undergone a hysterectomy and 84 
bilateral salpingo-oopherectomy for ovarian cancer at age 44 years and endoscopic removal of 85 
a malignant colonic polyp at age 47 years. Clinical examination revealed right loin tenderness 86 
but was otherwise unremarkable with no evidence of catecholamine, glucocorticoid, 87 
mineralocorticoid or androgen excess. Abdominal ultrasonography demonstrated a right 88 
suprarenal lesion and subsequent computed tomography (CT) confirmed the presence of a 14 89 
cm mass arising from the right adrenal gland. There was no evidence of extra-adrenal disease. 90 
Biochemical investigations excluded phaeochromocytoma and confirmed a non-secretory 91 
adrenal lesion. 92 
 93 
The patient underwent a laparoscopic right adrenalectomy and nephrectomy to remove a 14 x 94 
10cm adrenal mass. Pathological examination of the resected specimen showed an 95 
adrenocortical tumour with adrenal capsular invasion, areas of confluent necrosis and possible 96 
vascular invasion (Figure 2A (a) and (b)). The tumour was composed of lobules of oncocytic 97 
cells separated by fibrous septae. The tumour cells showed focal marked nuclear pleomorphism 98 
with bizarre nuclear forms. The mitotic index was 1/50hpf. Immunohistochemically, tumour 99 
cells were positive for vimentin and melan A and negative for calretinin, inhibin, S100, 100 
cytokeratin, carcinoembryonic antigen (CEA), chromogranin A, neurofilament (NFP) and 101 
synaptophysin. Collectively, these features were in keeping with an oncocytic adrenocortical 102 
carcinoma based on Lin-Weiss-Bisceglia criteria (4,5). 103 
 104 
Adjunctive mitotane therapy (maximum tolerated dose: 500mg thrice daily) was commenced 105 
with concurrent hydrocortisone replacement (10mg twice daily). To date the patient has 106 
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received regular clinical, biochemical and radiological surveillance with no evidence of disease 107 
recurrence.   108 
 109 
The proband’s sister (Patient III:1) had no significant personal medical history until age 36 110 
years when she was diagnosed with an adenocarcinoma of the descending colon which required 111 
a left hemicolectomy. At age 47 years she was diagnosed with endometrial carcinoma following 112 
investigations for intermenstrual bleeding, and treated by radical hysterectomy. 113 
 114 
An underlying familial cancer syndrome was suspected and a more detailed family history 115 
revealed that the proband’s maternal aunt (Patient II:3) and grandfather (Patient I:1) had both 116 
been diagnosed with colorectal cancer (Figure 1). Importantly, the certificate of death for the 117 
proband’s mother (Patient II:2) stated metastatic adrenocortical carcinoma as the cause of death. 118 
Given the rarity and difficulty in establishing malignancy of adrenocortical tumours, the 119 
histology of the resected adrenal tumour was re-evaluated which, confirmed the original 120 
diagnosis of primary adrenocortical carcinoma (Figure 2A(c)).  121 
 122 
In accordance with the Amsterdam II criteria and revised Bethesda criteria the family fulfilled 123 
diagnostic requirements for Lynch syndrome and further immunohistochemistry was performed 124 
on both ACCs (Patients III:2 and II:2) and the endometrial tumour (Patient III:1) to determine 125 
MMR protein expression status (Figure 2B) (2).  In all analysed tumours expression of MLH1 126 
and PMS2 was retained whilst nuclear staining for MSH2 and MSH6 were absent, consistent 127 
with a LS phenotype. Further germline genetic testing was undertaken by multiplex ligation 128 
dependent probe amplification (MLPA) analysis in the proband and her sister and revealed a 129 
heterozygous deletion of exons 1, 2 and 3 of the MSH2 gene. Further genetic testing also 130 
identified the mutation in the proband’s son (Patient IV:5), daughter (Patient IV:4) and niece 131 
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(Patient IV:2). In accordance with the Chompret testing criteria, TP53 germline mutations were 132 
excluded in the proband (6). The unavailability of genomic DNA from the proband’s mother 133 
(Patient II:2) precluded further genetic study.   134 
 135 
  136 
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Discussion 137 
ACC is not currently included in the diagnostic criteria for Lynch syndrome. However, our 138 
description of familial ACC arising in the context of a germline MSH2 mutation supports the 139 
recent proposal that ACC should be considered a LS-associated tumour (3). Currently, the 140 
diagnosis of LS requires patients/kindreds to fulfil the Amsterdam or revised Bethesda criteria, 141 
with demonstration of absent MMR protein expression on tumour immunohistochemistry 142 
and/or microsatellite instability (MSI) genotyping supporting the diagnosis (2). Genetic testing 143 
for germline mutations in MMR genes is reserved for individuals with tumours that demonstrate 144 
MSI or absent MMR protein expression, or those deemed at-risk based on computational 145 
prediction models (2).   146 
 147 
Isolated cases of ACC arising in single patients of families with LS and germline mutations in 148 
DNA MMR genes (MLH1, MSH2, MSH6) have been previously reported, but given their rarity, 149 
determining whether these tumours were coincidental or part of the LS tumour profile has 150 
remained controversial (3,7,8). Compelling evidence supporting ACC as a LS-associated 151 
cancer was recently provided by Raymond and colleagues who found that LS prevalence among 152 
patients with primary ACC was significantly higher (3.2%) than in the background population 153 
(0.2%), and comparable to the prevalence of LS in colorectal (2-4%) and endometrial cancer 154 
(1-5%) (3). Moreover, the prevalence of ACC in LS was increased compared with the general 155 
population. Given that ACC is typically an aggressive malignancy, with limited treatment 156 
options for advanced disease, recognising association of this tumour with LS has important 157 
clinical implications. Specifically, improved awareness and recognition of the syndrome and 158 
entry into appropriate systematic cancer surveillance programmes would be anticipated to lead 159 
to earlier diagnosis and timely intervention in order to reduce LS-related morbidity and 160 
mortality.  161 
  9
 162 
IHC analysis of tumour MMR proteins is often performed concomitantly with MSI to improve 163 
clinical sensitivity in the evaluation for LS. In our case, IHC analysis for LS-related tumours 164 
was informative and identified loss of MSH2 and MSH6 expression in the ACC and 165 
endometrial tumours analysed from affected patients with the germline MSH2 mutation.  In 166 
contrast with colorectal tumours, which demonstrate high MSI, previous reports have 167 
consistently found that ACC tumours have low MSI in patients with LS, and on this basis MSI 168 
testing was not performed in our patient (3). Whilst a molecular basis for this discrepancy 169 
between tumour types remains unclear, it has been proposed that in some tumours, possibly due 170 
to tissue-specific factors, the consequences of MMR deficiency occur in the latter stages of 171 
carcinogenesis thereby preventing detectable accumulation of MSI. Further, currently used MSI 172 
tests have been optimised for colorectal cancers and are less sensitive for MSI detection in other 173 
tumour types. Therefore, low MSI does not necessarily exclude a diagnosis of LS and, for both 174 
sporadic and familial ACC, IHC analysis of MMR proteins should be considered the first-line 175 
molecular screening strategy, even in individuals without other LS-associated lesions, with 176 
germline genetic testing pursued in the absence of one or more MMR proteins. Currently, there 177 
are no established biochemical or radiological screening guidelines for those at-risk of ACC. 178 
We have adopted an empirical approach in the offspring of our proband, combining periodic 179 
surveillance MRI imaging MRI with serum and urinary steroid profiling. It remains to be seen 180 
whether this is a clinically cost-effective approach. 181 
 182 
In summary, we report the first description of familial ACC in conjunction with a germline 183 
MSH2 mutation and provide support for MMR genes as candidates in hereditary ACC. We 184 
advocate ACC be now included in clinical diagnostic criteria for LS and considered in cancer 185 
surveillance strategies for individuals with germline mutations in DNA MMR genes. Moreover, 186 
  10
in the absence of clinical management guidelines for ACC surveillance in patients with 187 
inherited cancer syndromes, including LS, we recommend individualised screening protocols 188 
coupled with ongoing clinical vigilance.  189 
 190 
 191 
  192 
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Figure Legends 235 
 236 
Figure 1. 237 
Pedigree of family with the germline MSH2 mutation. NN represents wild-type individuals and 238 
NM denotes carriers of the mutation.  239 
 240 
Figure 2. 241 
(A) (a) High magnification image of H&E stained photomicrograph demonstrating confluent 242 
tumour necrosis (arrowhead) in ACC from patient II:2. (b) Medium magnification image 243 
demonstrating capsular invasion (arrowhead) in ACC from patient II:2. (c) Medium 244 
magnification image of ACC from patient III:2 demonstrating atypical nuclei, mitotic activity 245 
and areas of necrosis.  246 
 247 
(B) Immunohistochemical analyses of MLH1, PMS2, MSH2 and MSH6 protein expression in 248 
adrenocortical carcinomas (ACC) resected from Patients II:2 (a,b,c,d) and III:2 (e,f,g,h), and 249 
endometrial tumour resected from Patient III:1 (i,j,k,l) (x400). All analysed tumours retained 250 
expression of MLH1 (a,e,i) and PMS2 (b,f,j) (short arrowhead) but expression of MSH2 (c,g,k) 251 
and MSH6 (d,h,l) was absent (solid arrow) with adjacent normal stromal cells exhibiting 252 
positive staining (dashed arrow). 253 
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